More than a week after SpaceX’s highly anticipated debut on Nasdaq, market dynamics surrounding the offering have drawn comparisons to some of the most turbulent episodes in recent financial history. The company launched its shares at $15 each on June 12, experiencing a rapid surge of over 40 percent within two days. While the stock remains up approximately 15 percent from its initial price, currently valuing the company at roughly $2.06 trillion, the share price has retreated significantly from its peak.

The landmark initial public offering (IPO) raised about $75 billion, marking it as the largest in history. However, what set this IPO apart was its unusual structure: roughly 30 percent of shares were reserved specifically for retail investors, with a public free float around 5 percent. This deliberate limitation generated intense demand, reportedly four times oversubscribed, leading many buyers to chase shares on the secondary market.

Compounding this dynamic was the introduction of an options market for the stock shortly after listing. Heavy retail participation in short-dated call options—financial instruments often likened to lottery tickets—triggered a hedging mechanism whereby market makers bought underlying shares to cover potential exposure. This feedback loop, driven by constrained supply and elevated demand, propelled SpaceX’s stock to an intraday high of $226 per share, briefly valuing the company near $2.95 trillion.

It remains uncertain whether this phase of heightened speculative activity has run its course, especially with index fund purchases anticipated to commence soon. The current environment echoes the mechanics behind previous retail-driven market phenomena such as GameStop’s short squeeze in 2021, raising concerns over a potential correction as the stock trades at an unprecedented valuation without current earnings.

Meanwhile, some established industry leaders are seeing their valuations compressed despite solid financial performance. Companies like ResMed, a dominant player in respiratory care and CPAP therapy, recently reported 10 percent growth and is forecasted to achieve approximately 30 percent earnings per share growth over the next three years. It holds $1 billion in net cash and maintains a return on invested capital exceeding 25 percent. Yet, its shares trade near a 52-week low at about 15 times forward earnings, down from a five-year average of roughly 29 times. Market apprehension centers on concerns over the impact of GLP-1 weight-loss drugs on ResMed’s patient base, though clinical evidence suggests these fears may be overstated as demand for CPAP treatment continues to rise.

Similarly, Steadfast, Australia’s leading insurance broker, endured depressed valuations amid fears that artificial intelligence would disrupt its business model. Despite these concerns, the company has continued steady earnings growth of 6 to 10 percent and recently attracted a takeover offer representing a 52 percent premium over its trading price, which had been near historic lows around an 11 times earnings multiple—well below its long-term average of 20 times.

Financial experts caution that while SpaceX’s long-term prospects may be strong given Elon Musk’s track record, the stock’s current pricing and structural factors introduce considerable risk. The combination of a limited free float, speculative options activity, and a lofty valuation with no current earnings makes the risk-reward profile unfavorable for new investors at this stage.

Analysts highlight that enduring investment success often stems from focusing on companies with solid fundamentals that are temporarily out of favor rather than chasing the market’s most hyped assets. In this context, selecting businesses with consistent earnings, robust competitive advantages, and effective pricing power may offer more sustainable returns than engaging in speculative frenzies.

As the SpaceX story unfolds, it serves as a reminder that the excitement around a high-profile IPO can mask underlying market imbalances. Historically, episodes fueled by retail enthusiasm and constrained supply have frequently culminated in sharp corrections, underscoring the value of disciplined investment grounded in fundamentals over narrative-driven speculation.